Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Thirty biosimilars are currently marketed in the United States and Europe alone. While Europe has long led the way in terms of biosimilars guidelines and clinical development, other countries/regions are catching up, fast. Clinical development of biosimilars is taking place across the globe, increasingly in emerging markets. Download our infographic to find out more about where the biosimilars hotspots are.